Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1149
Peer-review started: March 7, 2021
First decision: July 15, 2021
Revised: July 18, 2021
Accepted: September 16, 2021
Article in press: September 16, 2021
Published online: October 27, 2021
Processing time: 233 Days and 0.6 Hours
Core Tip: Transanal minimally invasive surgery (TAMIS) was introduced in 2010 as a crossover between single-incision laparoscopic surgery and transanal endoscopic microsurgery (TEM). The TAMIS technique can be resected to the proximal and mid-rectal lesion for benign, early-stage cancer, and more advanced lesions in selective patients. TAMIS is an easily accessible, technically feasible, and cost-effective alternative to TEM. TAMIS has proven its usefulness in a wide range of applications outside of local excision, including pelvic abscess drainage, rectal stenosis, and treatment of anastomotic dehiscence. TAMIS like TEM and transanal endoscopic operation with platform difference can achieve the high-quality excision superior to traditional TAE or endoscopic resection, despite the limitations of evidence for large volume or randomized controlled studies.
